Intermediates & Key Starting Material
Intermediates & Key Starting Material
Intermediates and Key Starting Materials (KSMs) are the chemical building blocks used earlier in the synthesis route of an Active Pharmaceutical Ingredient. Strong intermediate and Key Starting Material capability gives API manufacturers better control over cost, quality, and supply security.
At Noventis Life Sciences, our Intermediate and Key Starting Material portfolio is one of our biggest strengths. It spans building blocks for both well-established APIs and a number of newer, more complex molecules across oncology-support, CNS, cardiovascular, anti-infective, and metabolic chemistry — reflecting our chemistry team’s ability to handle demanding, multi-step synthesis.
We supply these intermediates and Key Starting Material to API manufacturers and CDMOs looking to backward-integrate their supply chain, reduce dependency on single-source suppliers, or develop a specific synthesis route.
Our Intermediates & Key Starting Material Products
| Chemical Name | CAS No. | API |
| 5-(2-Fluoro-Phenyl)-1-(Pyridine-3-Sulfonyl)-1H-Pyrrole-3-Carbaldehyde (N-1) | 881677-11-8 | Vonoprazole |
| 2,N-Dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol | 100442-33-9 | Lercanidipine |
| 2,6-Dimethy|-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid monomethyl ester | 74936-72-4 | Lercanidipine |
| 6-CHLOROURACIL | 4270-27-3 | Alogliptin |
| 2-(BROMOMETHYL) BENZONITRILE | 22115-41 | Alogliptin |
| 3,3-Dimethyl Butan-2-one (Pinacolon) | 75-97-8 | Stiripentol |
| 5-Chloro-2-mercaptobenzoxazole | 22876-19-3 | Suvorexant |
| (5R)-1-BENZYL-S-METHYL-1,4-DIAZEPANE | 1620097-06-4 | Suvorexant |
| (E )-Phenyl Diazenylmalonitrile | 6017-21-6 | Vericiguat |
| 2-Hydroxy-3-Nitrobiphenyl-3-Carboxylic Acid | 376591-95-6 | Eltrombopag |
| Sodium 8-(2-hydroxybenzamido)Octanoate | 203787-91-1 | Slacaprazote Sodium |
| 6-Methyl-2-(4-Methyl Phenyl) Imidazo[1,2-a]Pyridine | 88965-00-8 | Zolpidome |
| Pyrimidine-2-(1H)-one Hydrochloride | 38353-09-2 | Piribidile |
| 4-Amino-5-Chloro-2,3-Dihydro-1-Benzofuran-7-Carboxylic Acid | 123654-26-2 | Prucalopride |
| 2,3-Dichloronitrobenzene | 3209-22-1 | Lamotrigine |
| 2,3-Dichlorobenzoyl chloride | 2905-60-4 | Lamotrigine |
| 6-fluoro-3,4-dihydro-2-oxiranyl-2H-1-benzopyran | 99199-90-3 | Nebivolol |
| (±)-[1S*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl-2H-1-Benzopyran OR (±)- [1S*(R*)]-6-Fluoro-2- oxiranylchroman OR (±) – (R*)-6-Fluoro- 2-[(S*)- oxiran-2-yl) chroman (ISOMER A) | 793669-26-8 | Nebivolol |
| (±)-[1R*(R*)]-6-Fluoro-3,4-Dihydro-2-Oxiranyl -2H-1-Benzopyran OR (±) – [1R*(R*)]-6-Fluoro-2- oxiranyl- chroman OR (±)-(R*)-6-Fluoro- 2-[(R*)- oxiran-2-yl) chroman (ISOMER B) | 876514-31-7 | Nebivolol |
| 4-Morpholinopiperidine | 53617-35-9 | Alectinib |
| 2,4-Dichloro-5-fluoropyrimidine | 2927-71-1 | Abemaciclib |
| 3-Acetylaminophthalic Anhydride | 6296-53-3 | Apremilast |
| (R)-Boroleucine (1S 2S 3R 5S)-(+)-2 3-pinanediol ester trifluoroacetate | 179324-87-9 | Bortizomib |
| N-Pyrazinylcarbonyl-L-phenylalanine | 114457-94-2 | Bortizomib |
| 2-Bromo-2′-chloroacetophenone | 5000-66-8 | Cenobamate |
| 1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl) ethanone | 1259059-71-6 | Cenobamate |
| (R)-1-(2-chlorophenyl)-2-(2H-tetrazol-2-yl)ethanol | 1259059-77-2 | Cenobamate |
| L-Phenylalanine, (αS)-α-aminobenzenebutanoyl-L-leucyl-, methyl ester, hydrochloride | 1960444-13-6 | Carfilzomib |
| Alanine, N-L-leucyl-3-phenyl-, mono(trifluoroacetate) | 16944-24-4 | Carfilzomib |
| 4-Amino-2-fluoro-N-methylbenzamide | 915087-25-1 | Enzalutamide |
| 1-(3-Methoxypropyl)-4-piperidinamine | 179474-79-4 | Prucalopride |
| 1,3-Dihydro-1-[(1H-imidazol-1-ylcarbonyl)-4-piperidinyl]-2H-imidazo[4,5-b]pyridin-2-one | 1373116-06-3 | Rimegepant |
| 4-(bromomethyl)-1-cyclohexyl-2-(trifluoromethyl)benzene | 800381-60-6 | Siponimod |
| O-(4-cyclohexyl-3-(trifluoromethyl)benzyl)hydroxylamine | 800379-62-8 | Siponimod |
| 3-Azetidinecarboxylic acid | 36476-78-5 | Siponimod |
| Sodium (S)-4-oxo-4,6,7,8-tetrahydropyrrolo[1,2-a]pyrimidine-6-carboxylate | 1421271-01-3 | Vibegron |
| 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)methyl) benzoic acid | 763114-26-7 | Olaparib |
| Tert-Butyl 2-((1,3-dioxoisoindolin-2-yl)oxy)-2-methylpropanoate | 76028-85-8 | Cefiderocol |
Why Backward Integration Matters
Sourcing intermediates and KSMs from a dedicated manufacturer — rather than relying solely on the final API supplier — gives formulation companies better cost control, supply security, and the flexibility to qualify alternate synthesis routes.
Built for Complex, New-Generation Molecules
A significant part of this portfolio supports newer therapeutic molecules rather than only legacy generics — chemistry that demands precision and tight process control. It’s a reflection of where we’re investing our R&D attention as a company.
Custom Synthesis
If you’re developing a synthesis route for a specific API and need a particular intermediate or KSM, talk to us — we’re well set up to take on custom development and scale-up projects.
